Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis

JM. Ten Berg, A. de Veer, J. Oldgren, PG. Steg, DA. Zateyshchikov, P. Jansky, KB. Seung, SH. Hohnloser, GYH. Lip, M. Nordaby, E. Kleine, DL. Bhatt, CP. Cannon, RE-DUAL PCI Steering Committee and Investigators,

. 2019 ; 12 (23) : 2331-2341. [pub] 20191209

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025411

OBJECTIVES: The aim of this study was to assess if prior oral anticoagulant agent (OAC) use modifies the lower bleeding risk observed with dabigatran dual therapy (dabigatran twice daily plus a P2Y12 inhibitor) versus warfarin triple therapy (warfarin plus a P2Y12 inhibitor plus aspirin) in patients with atrial fibrillation who underwent percutaneous coronary intervention (PCI). BACKGROUND: In the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial, the primary outcome of major bleeding or clinically relevant nonmajor bleeding was lower with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation who underwent PCI. METHODS: A total of 2,725 patients were randomized to dual therapy with dabigatran (110 or 150 mg twice daily) plus clopidogrel or ticagrelor or triple therapy with warfarin plus aspirin and clopidogrel or ticagrelor. Subgroup analysis compared risk for major bleeding or clinically relevant nonmajor bleeding and a composite thromboembolic endpoint in patients with prior OAC use and in those who were OAC treatment naive. RESULTS: Risk for major bleeding or clinically relevant nonmajor bleeding was reduced with both dabigatran dual therapies compared with warfarin triple therapy in both the prior OAC use group (hazard ratios: 0.58 [95% confidence interval (CI): 0.42 to 0.81] and 0.61 [95% CI: 0.41 to 0.92] with 110 and 150 mg dabigatran, respectively) and the OAC-naive group (hazard ratios: 0.49 [95% CI: 0.38 to 0.63] and 0.76 [95% CI: 0.59 to 0.97] with 110 and 150 mg dabigatran) (p for interaction = 0.42 and 0.37, 110 and 150 mg dabigatran, respectively). The risk for thromboembolic events seemed similar with dabigatran dual therapy (both doses) and warfarin triple therapy across subgroups. CONCLUSIONS: Bleeding risk was reduced with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation after PCI, regardless of whether they were prior OAC users or OAC treatment naive. These results suggest that it is also safe to switch patients on OAC pre-PCI to dabigatran dual therapy post-PCI.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025411
003      
CZ-PrNML
005      
20201222155200.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcin.2019.08.039 $2 doi
035    __
$a (PubMed)31806214
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ten Berg, Jurrien M $u St. Antonius Ziekenhuis, Nieuwegein, the Netherlands. Electronic address: jurtenberg@gmail.com.
245    10
$a Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis / $c JM. Ten Berg, A. de Veer, J. Oldgren, PG. Steg, DA. Zateyshchikov, P. Jansky, KB. Seung, SH. Hohnloser, GYH. Lip, M. Nordaby, E. Kleine, DL. Bhatt, CP. Cannon, RE-DUAL PCI Steering Committee and Investigators,
520    9_
$a OBJECTIVES: The aim of this study was to assess if prior oral anticoagulant agent (OAC) use modifies the lower bleeding risk observed with dabigatran dual therapy (dabigatran twice daily plus a P2Y12 inhibitor) versus warfarin triple therapy (warfarin plus a P2Y12 inhibitor plus aspirin) in patients with atrial fibrillation who underwent percutaneous coronary intervention (PCI). BACKGROUND: In the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial, the primary outcome of major bleeding or clinically relevant nonmajor bleeding was lower with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation who underwent PCI. METHODS: A total of 2,725 patients were randomized to dual therapy with dabigatran (110 or 150 mg twice daily) plus clopidogrel or ticagrelor or triple therapy with warfarin plus aspirin and clopidogrel or ticagrelor. Subgroup analysis compared risk for major bleeding or clinically relevant nonmajor bleeding and a composite thromboembolic endpoint in patients with prior OAC use and in those who were OAC treatment naive. RESULTS: Risk for major bleeding or clinically relevant nonmajor bleeding was reduced with both dabigatran dual therapies compared with warfarin triple therapy in both the prior OAC use group (hazard ratios: 0.58 [95% confidence interval (CI): 0.42 to 0.81] and 0.61 [95% CI: 0.41 to 0.92] with 110 and 150 mg dabigatran, respectively) and the OAC-naive group (hazard ratios: 0.49 [95% CI: 0.38 to 0.63] and 0.76 [95% CI: 0.59 to 0.97] with 110 and 150 mg dabigatran) (p for interaction = 0.42 and 0.37, 110 and 150 mg dabigatran, respectively). The risk for thromboembolic events seemed similar with dabigatran dual therapy (both doses) and warfarin triple therapy across subgroups. CONCLUSIONS: Bleeding risk was reduced with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation after PCI, regardless of whether they were prior OAC users or OAC treatment naive. These results suggest that it is also safe to switch patients on OAC pre-PCI to dabigatran dual therapy post-PCI.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $7 D000925
650    _2
$a Aspirin $x aplikace a dávkování $7 D001241
650    _2
$a fibrilace síní $x diagnóza $x farmakoterapie $x mortalita $7 D001281
650    _2
$a klopidogrel $x aplikace a dávkování $7 D000077144
650    _2
$a nemoci koronárních tepen $x diagnostické zobrazování $x mortalita $x terapie $7 D003324
650    _2
$a dabigatran $x aplikace a dávkování $7 D000069604
650    12
$a náhrada léků $x škodlivé účinky $7 D057915
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x chemicky indukované $x diagnóza $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a koronární angioplastika $x škodlivé účinky $x mortalita $7 D062645
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $x škodlivé účinky $7 D010975
650    _2
$a rizikové faktory $7 D012307
650    _2
$a ticagrelor $x aplikace a dávkování $7 D000077486
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a warfarin $x aplikace a dávkování $7 D014859
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a de Veer, Anne $u St. Antonius Ziekenhuis, Nieuwegein, the Netherlands.
700    1_
$a Oldgren, Jonas $u Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
700    1_
$a Steg, Philippe Gabriel $u French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, Paris, France; Université de Paris, Paris, France; INSERM U-1148, Paris, France; Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.
700    1_
$a Zateyshchikov, Dmitry A $u Primary Vascular Department, City Clinic Hospital #51, Moscow, Russian Federation.
700    1_
$a Jansky, Petr $u Department of Cardiovascular Surgery, Faculty Hospital Motol, Prague, Czech Republic.
700    1_
$a Seung, Ki-Bae $u The Catholic University of Korea, Seoul, Korea.
700    1_
$a Hohnloser, Stefan H $u Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
700    1_
$a Lip, Gregory Y H $u Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
700    1_
$a Nordaby, Matias $u Boehringer Ingelheim International, Ingelheim, Germany.
700    1_
$a Kleine, Eva $u Boehringer Ingelheim International, Ingelheim, Germany.
700    1_
$a Bhatt, Deepak L $u Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts.
700    1_
$a Cannon, Christopher P $u Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts.
710    2_
$a RE-DUAL PCI Steering Committee and Investigators
773    0_
$w MED00186218 $t JACC. Cardiovascular interventions $x 1876-7605 $g Roč. 12, č. 23 (2019), s. 2331-2341
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31806214 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155156 $b ABA008
999    __
$a ok $b bmc $g 1599556 $s 1116097
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 12 $c 23 $d 2331-2341 $e 20191209 $i 1876-7605 $m JACC. Cardiovascular interventions $n JACC Cardiovasc Interv $x MED00186218
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace